Introduction ( )-Podophyllotoxin (1) is a lignan of aryltetralin family found in the plants like
Podophyllum peltatum and Podophyllum emodi. 1 Interest in podophyllotoxin has been heightened by its potent antimitotic activity 2, 3 and it inhibits the assembly of tubulin protein into microtubules through tubulin binding at the colchicine site. 4, 5 However, it failed to advance in human clinical trials because of toxic side-effects. Extensive structural modifications have been performed since 1950s, principally at Sandoz Laboratories, 6, 7 which led to the semi-synthetic derivatives, etoposide (2) 8 and teniposide (3, Figure 1 ). 9, 10 Both these derivatives demonstrated significant activity with lower toxicity in clinical trials and they target DNA topoisomerase-II . 11 These are currently being used as frontline cancer chemotherapeutics against various cancers, including small-cell lung cancer, testicular carcinoma, lymphoma, and Kaposi's sarcoma. 12 However, their therapeutic use has encountered certain limitations such as acquired drug resistance, and lower bioavailability. To overcome such problems, extensive synthetic efforts have been carried out by a number of researchers. This led to the development of NK-611 (4) and GL-331 (5), which are in different stages of clinical studies and exhibit improved cytotoxicity as well as DNA topoisomerase-II inhibition. 13 It has also been indicated in the literature that bulky substitution at the C-4 position of the podophyllotoxin usually enhances the cytotoxicity and DNA topoisomerase-II inhibition activity. [14] [15] [16] [17] [18] [19] Similarly, the urea derivatives such as bis-aryl ureas have been most extensively investigated new chemical entities following the success of Sorafenib 20 for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. 21, 22 More importantly, this class of urea derivatives have been found to be potent inhibitors of human DNA topoisomerase-I and II . [23] [24] [25] DNA topoisomerase-I and topoisomerase-IIα enzymes are expressed at different levels in different cell types; the expression of topoisomerase-I is prominent in colon cancer cell lines, while topoisomerase-II is high in breast and ovarian cancer cell lines. 26 The expression of either of the enzyme, sufficient to support cell division and the development of resistance to topoisomerase-I inhibitors is often accompanied by a concomitant rise in the level of topoisomearse-IIα and vice versa. 27, 28 Thus dual inhibitors of topoisomerase-I and topoisomerase-IIα may have advantages and there has been much interest in such compounds in clinical evaluation, including intoplicine and XR 500016. 29, 30 In our ongoing research efforts to design and develop new potent anticancer agents,
we have been involved for many years in the synthesis and in vitro biological evaluation of podophyllotoxin congeners. [31] [32] [33] [34] [35] [36] [37] In continuation of these efforts, we have undertaken the synthesis of some new analogues of podophyllotoxin by linking it to a urea moiety through an aryl amino spacer at C-4 position of the podophyllotoxin scaffold with a view to combine the pharmacological characteristics of both these chromophores. In the present study, we report the synthesis and in vitro cytotoxic activity of a series of novel 4β-[4 -(1-(aryl)ureido)benzamide]podophyllotoxin derivatives (11a-l). Most of these podophyllotoxin derivatives have exhibited better cytotoxicity than etoposide. Based on their promising in vitro cytotoxicity, it was considered of interest to investigate their role in the cell proliferation apart from their effect on DNA topoisomerase-I and II inhibition.
<Insert Figure 1> 
Results and Discussion

Chemistry
The new 4β- [4 -(1-(aryl) 
Anti-proliferative activity
All the compounds 11a-l were evaluated for their anti-proliferative activity in selected human cancer cell lines of breast, oral, colon, lung and ovarian origin by using sulforhodamine B (SRB) method. 38 The compounds that exhibit GI 50 10 −5 M are considered to be active in the respective cell lines and the results are illustrated in Table   1 . All the compounds 11a-l exhibit significant anti-proliferative activity with GI 50 values ranging from 0.01 to 2.90 µM, while the positive controls, etoposide and adriamycin demonstrated the GI 50 in the range of 0.13 to 3.11 µM and 0.10 to 7.25 µM, respectively.
Based on the cytotoxicity data, the structure activity relationship (SAR) was examined for these new podophyllotoxin congeners (11a-l). It is interesting to observe that one of the compounds 11a with chloro substitution at para-position of the phenyl ring showed similar or slightly reduced activity in comparison to the methoxy substitution 11h. Both these compounds 11a and 11h displayed potent cytotoxic activity against different cell lines such as colon, breast and lung cancer cell lines, which were similar or better than etopside. However, shifting the chloro group from para-position (11a) to the metaposition (11b) remarkably decreased the cytotoxicity, suggesting that the electron distribution pattern on benzoyl urea side chains probably play an important role towards the activity profile. Moreover, the presence of different disubstitutions on phenyl ring such as 2,6-dichloro (11c), 3,5-dimethyl (11f), 3,5-ditrifluoromethyl (11g) and 3-flouro -4-chloro (11e) groups at different positions of the phenyl ring determined a marked decrease or no inhibitory activity on these cancer cell lines. In addition, the introduction of heterocyclic motifs into urea side chain, such as furan (11d) and thiophene (11j) exhibited marginal or no activity against the different human tumor cell lines, while 11d
showed selective activity towards MCF7 and DWD cell lines. It is also observed that the removal of the phenyl ring and substitution with aliphatic side chains like 2-chloro ethyl (11k) and 2-bromo ethyl (11l) derivatives resulted in enhancement of activity and is comparable to that of etoposide. Interestingly, all the synthesized compounds 11a-l showed potent cytotoxic activity against MCF7 cell lines. 39 clearly indicated that the effect of these podophyllotoxins on the cell viability ( Figure 2B and 2C).
<Insert Table 1> <Insert Figure 2A> <Insert Figure 2B> <Insert Figure 2C> 
Effect on cell cycle
In order to understand the role of these new podophyllotoxin conjugates 11a, 11h, 11k and 11l, on cell cycle regulation, flow-cytometric analysis was conducted in colon cancer cells (Colo-205) at 2 µM concentration for 24 h. It was observed that Colo-205 cells showed 78%, 76%, 76% and 72% of G1 phase cell cycle arrest in cells treated with 11a, 11h, 11k and 11l respectively, whereas control (untreated cells) exhibited 65%.
However, standard drug showed G2/M phase cell cycle arrest ( Figure 3) . Interestingly, DNA topoisomerase-II inhibitors were also known to cause G1 cell cycle arrest. 40 <Insert Figure 3> 
Effect on DNA topoisomerase enzyme
The DNA topoisomerase-II enzyme inhibition assay was examined in comparison to etoposide. The pBR322 plasmid was incubated with DNA topoisomerase-IIα enzyme that causes relaxed DNA. The effect of these compounds 11a-l on topoisomerase-IIα was compared with etoposide as standard topoisomerase II inhibitor at 2 µM concentration as shown in Figure 4A . These results were clearly demonstrated that these new compounds in particular 11a, 11h, 11k, 11l displayed significant inhibitory activity on topoisomerase-II . Further, we have also tested these compounds for inhibitory activity on DNA topoisomerase-I. To our surprise, 11a exhibits topo-I inhibition and is comparable with respect to camptothecin (CPT), a standard topoisomerase-I inhibitor ( Figure 4B ).
Thus, 11a causes significant inhibition of both topoisomerase-I as well as topoisomerase-II enzymes.
<Insert Figure 4A and 4B>
Effect on caspase-3
Caspases belong to cysteine protease family and plays a crucial role in the induction of apoptosis. 41 Previous studies have reported that etoposide, a DNA topoisomerase-II inhibitor causes apoptosis by elevating the levels of caspase-3 protein. 42 These aspects were examined by treating the compounds 11a, 11h, 11k and 11l with Colo-205 cells at 2 µM concentration for 24 h and compared with etoposide. The lysates obtained were subjected to caspase-3 based ELISA and Western blot analysis. It was observed that caspase-3 was up-regulated with compound treated cells particularly in case of 11a as well as etoposide. The order of performance with regard to caspase-3 activation is 11a>etoposide>11h>11k>11l as shown in Figure 5A , and 5B.
<Insert Figure 5A and 5B>
It was considered of interest to examine DNA fragmentation and morphological changes associated with apoptosis as caspase-3 is known to be responsible for causing apoptosis. 43, 44 Colo-205 cells were treated with 11a (most potent compound) and etoposide (Eto) at 2 and 4 µM concentrations for 24 h, and nuclear staining was performed by using Hoechst stain. It was observed that the compound treated cells showed DNA fragmentation and blebbing, whereas control cells did not show such blebbing, thereby revealing that these compounds induce apoptosis as shown in Figure 6 .
<Insert Figure 6> 
Molecular docking studies
To evaluate the binding modes and nature of interactions for some of these potent compounds like 11a, 11h, 11k, and 11l with active site residues of human DNA topoisomerase I as well as topoisomerase IIα, docking studies were performed by using shows interaction with adenine moiety, A113 and π-π stacking interaction between trimethoxy phenyl moiety of 11a and TGP11 in human DNA topoisomerase-I ( Figure   7C ), confirming its dual affinity towards both topoisomerase-I and topoisomerase-IIα enzymes.
<Insert Figure 7A> <Insert Figure 7B> <Insert Figure 7C> 
Conclusion
In 
Experimental Section
All chemicals and reagents were obtained from Aldrich N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9 N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9 
N1-((5S
,
6.6.N1-((5S
6.8.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro [1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((3,5-dimethylanilino)carbonyl )amino)benzamide (11f): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
trimethoxyphenyl)-5,
6.10.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro [1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-(((4-methoxyanilino)carbonyl) amino)benzamide (11h): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-
6.11.N1-((5S
6.13.N1-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydro [1,3]dioxolo[4',5':4,5]benzo[f]isobenzofuran-5-yl)-4-((((2-chloroethyl)amino) carbonyl)amino)benzamide (11k): To a solution of N1-((5S,5aS,8aR,9R)-8-oxo-9-
Materials and Methods
Procedure of the SRB-assay:
The and OD of test growth in the presence of drug ¼ Ti.
Cell culture:
Human colon (Colo-205) and breast (MDA-MB-231) carcinoma cells were purchased from American Type Culture collection Centre (ATCC). Dulbecco's modified Eagle's medium (DMEM) (Invitrogen), supplemented with 2 mM glutamax (Invitrogen), 10% fetal calf serum and 100 U/ml Penicillin and 100 mg/ml streptomycin sulfate (Sigma) was used as growth media for MDA-MB-231 cells. RPMI medium supplemented with 10% FCS with appropriate antibiotics (Penicillin, Streptomycin and Kanamycin) was used for growing Colo-205 cells. These cell lines were maintained at 37 o C in a humidified atmosphere containing 5% CO 2 in the incubator.
MTT assay:
Individual wells of a 96-well tissue culture micro titer plate were inoculated with 100 µL of complete medium containing 1 10 4 cells. The plates were incubated at 37 °C in a humidified 5% CO 2 incubator for 18 h prior to the experiment. After medium removal, 100 µL of fresh medium containing the test compounds 11a, 11h, 11k, 11l and etoposide Histograms were analyzed using Summit Software.
DNA topoisomerase-IIα inhibition assay:
The 
DNA topoisomerase-I inhibition assay:
The activity of DNA topoisomerase-I was determined by assessing the relaxation of supercoiled DNA pBR322. The mixture of 500 ng of plasmid pBR322 DNA and 0.4 units of recombinant human DNA topoisomerase-I (TopoGEN INC., USA) was incubated without and with the synthesized compounds (11a-11l) at 37 0 C for 30 min in the relaxation buffer (10 mM Tris-HCl (pH 7.9), 150 mM NaCl, 0.1% bovine serum albumin, 1 mM spermidine, 5% glycerol). The reaction in the final volume of 10 µL was terminated by adding 2.5µ L of the stop solution containing 5% sarcosyl, 0.0025% bromophenol blue, and 25% glycerol. DNA samples were then electrophoresed on a 1% agarose gel.
Caspase-3 assay:
The caspase-3 fluorescent assay kit (Clonetech, CA) was applied to evaluate the caspase-3 activity, using the procedures provided by the manufacturer. Colo-205 cells were treated with compounds 11a, 11h, 11k, 11l and etoposide (Eto) at 2 µM concentration for 24h. Cell lysates were added to the 2X reaction buffer containing DTT and caspase substrate was added and incubation was carried out at 37 C for 1 h.
Readings were taken at excitation wavelength 400 nm and emission wavelength 505 nm.
Protein extraction and Western blot analysis:
Colo-205 human colon cancer cells were seeded in 60 mm dishes and were allowed to grow to attain 80% confluency for 24 h. Compounds (11a, 11h, 11k, 11l and etoposide 
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